These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27218635)

  • 1. Risk of Anaphylaxis With Intravenous Iron Products.
    DeLoughery TG
    JAMA; 2016 May 24-31; 315(20):2232. PubMed ID: 27218635
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of Anaphylaxis With Intravenous Iron Products.
    Wang C; Wong S; Graham DJ
    JAMA; 2016 May 24-31; 315(20):2232-3. PubMed ID: 27218636
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
    Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
    JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 5. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model.
    Toblli JE; Cao G; Giani JF; Dominici FP; Angerosa M
    Drug Res (Stuttg); 2015 Jul; 65(7):354-60. PubMed ID: 25050519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
    Prescrire Int; 2013 Sep; 22(141):206. PubMed ID: 24171212
    [No Abstract]   [Full Text] [Related]  

  • 7. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Potthoff SA; Münch HG
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P; Hahn KM
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
    Hörl WH
    Perit Dial Int; 2001; 21(5):527-8. PubMed ID: 11757843
    [No Abstract]   [Full Text] [Related]  

  • 11. In older adults, iron dextran and ferumoxytol each had higher anaphylaxis risk at ≤1 d than iron sucrose.
    Bannow BS
    Ann Intern Med; 2022 Aug; 175(8):JC95. PubMed ID: 35914266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should intravenous iron be upfront therapy for iron deficiency anemia?
    Auerbach M
    Pediatr Blood Cancer; 2011 Apr; 56(4):511-2. PubMed ID: 21298731
    [No Abstract]   [Full Text] [Related]  

  • 13. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal anaphylactic reaction to iron sucrose in pregnancy: iron-induced Kounis syndrome?
    Soufras GD; Kounis GN; Kounis NG
    Indian J Pharmacol; 2013; 45(6):642-3. PubMed ID: 24347784
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America.
    Bailie GR; Hörl WH; Verhoef JJ
    Arzneimittelforschung; 2011; 61(5):267-75. PubMed ID: 21755809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients.
    Kumbasar A; Gursu M; Kaya C; Ozturk S; Ergen A; Kemik A; Aydin Z; Uzun S; Karadag S; Kazancioglu R
    J Nephrol; 2012; 25(5):825-32. PubMed ID: 22307439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to iron sucrose in dialysis patients sensitive to iron dextran.
    Gupta A; Khaira A; Dogra M; Agarwal SK
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):744-5; author reply 745. PubMed ID: 20587886
    [No Abstract]   [Full Text] [Related]  

  • 20. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.